

## A Simple Protocol to Insert the Profinity eXact™ Tag Into Alternate Expression Vectors


### Introduction

The Profinity eXact affinity purification system yields purified, tag-free target protein in as little as 1 hour after lysate loading. This system utilizes an immobilized mutant subtilisin protease that binds the Profinity eXact tag with high affinity; upon addition of a fluoride-containing elution buffer, the protease is activated and the tag-free target protein is quickly released. The Profinity eXact tag is expressed as an N-terminal tag and contains an engineered cleavage recognition sequence (EEDKLFKAL) at its C-terminus. Cleavage occurs directly after this sequence. The majority of proteins are purified without any residual amino acids from the Profinity eXact tag. However, if cysteine or proline immediately follows the cleavage recognition site, cloning should be performed to introduce a two-amino acid spacer (Thr-Ser) prior to the starting amino acids of the target protein of interest. *E. coli* expression of a Profinity eXact fusion protein is easily accomplished with the Bio-Rad pPAL7 expression vector, which facilitates construction of an N-terminal Profinity eXact fusion tag with the protein expressed by the target DNA sequence. However, some users prefer to use other expression vectors in order to utilize alternative promoters, selection markers, or C-terminal affinity tags.

This article describes one method that can be used to quickly clone the Profinity eXact tag into a different expression vector. First, a PCR fragment containing the Profinity eXact tag is created with 5' and 3' sequences complementary to the insertion site of the expression vector to be modified. The two strands of the PCR fragment are then used as mutagenesis oligonucleotides to insert the new affinity tag into the expression vector or replace undesired sequences (for example, 6xHis tag) with the Profinity eXact tag. A modification of the manufacturer's instructions for the QuikChange XL site-directed mutagenesis kit (Stratagene Corporation) is used to create DNA sequences of up to 1 kb for insertion (Geiser et al. 2001). The example illustrated in this article describes the substitution of the Profinity eXact tag for the 6xHis tag within the Gateway pDEST17 vector (Invitrogen Corporation) (Figure 1).

### Step 1: Design Primers

Primers are designed to produce the Profinity eXact tag with 5' ends that are complementary to the flanking regions of the insertion/substitution site.




### Step 2: Perform PCR

The resultant double-stranded PCR fragment is used as oligos for the mutagenesis reaction.



### Step 3: Perform Mutagenesis

During the mutagenesis reaction, the Profinity eXact tag (A) replaces the original 6xHis (B) used in the pDEST17 vector.



### Step 4: Create Modified pDEST17 Vector

The pDEST17 vector containing the Profinity eXact tag is created.




Fig. 1. Outline of strategy to replace 6xHis tag of Gateway pDEST17 recipient vector with the Profinity eXact tag.

## Profinity eXact Cloning Protocol

Use this method to insert the Profinity eXact tag into any expression vector quickly and easily:

1. Use PCR to create the oligonucleotide fragments needed for use with the QuikChange XL site-directed mutagenesis kit (The fragments are too long — greater than 250 bases — for chemical synthesis).

Figure 2 shows the primers containing the Profinity eXact tag (red sequences) flanked by the DNA sequences complementary to the region surrounding the pDEST17 insertion/replacement site (blue and green sequences in Figures 2 and 3).




Fig. 2. Primer design and PCR setup to create mutagenesis oligos.




Fig. 3. Target pDEST17 vector DNA sequence. The region highlighted in blue represents the sequence that should be present on the 5'-end of the Profinity eXact forward primer. The region highlighted in green represents the sequence that should be present on the 5'-end of the Profinity eXact reverse primer. After the QuikChange XL mutagenesis kit reaction, the insertion site highlighted in yellow will be replaced by the Profinity eXact tag.

2. Purify the PCR product using a 1% ReadyAgarose™ gel.  
Figure 3 shows the complementary regions along with the insertion site in the pDEST17 vector DNA sequence.

3. Modify the pDEST17 vector using the QuikChange XL site-directed mutagenesis kit with the conditions illustrated in Figure 4.




Fig. 4. Mutagenesis reaction to create pDEST17 vector modification.

4. Treat the resulting PCR product with DpnI as described in the QuikChange XL protocol.
5. Use the DpnI-treated PCR product (5 µl) to transform *E. coli* cloning chemi-competent cells (50 µl, Bio-Rad catalog #156-3000).
6. Culture the putative transformant colonies.
7. Isolate the Profinity eXact tag-pDEST vector using mini prep DNA purification.

## Summary

Benefits of using the Profinity eXact fusion tag system include time savings, increased lab efficiency, and the ability to generate unadulterated, tag-free protein in under an hour. The ability to obtain a purified target protein, free of its fusion partner, may still be realized regardless of its use with the pPAL7 expression vector. Whether due to user preference or increased familiarity with other expression vectors, there remain certain impediments for researchers when it comes to adoption of a new cloning system. The example presented here demonstrates how the Profinity eXact tag can easily be used to replace another tag (for example, 6xHis) by being inserted into a non-pPAL expression vector of choice. Depending on the vector to be modified, the user may instead choose to perform restriction enzyme cloning or recombination-mediated techniques, both common alternative strategies for DNA manipulation.

## References

- Geiser M et al. (2001). Integration of PCR fragments at any specific site within cloning vectors without the use of restriction enzymes and DNA ligase. *Biotechniques* 31, 88-90, 92.
- Purification and preparation of fusion proteins and affinity peptides containing at least two adjacent histidine residues may require a license under U.S. patents 5,284,933 and 5,310,663, including foreign patents (assignee: Hoffmann-La Roche).
- Profinity exact vectors, tags, and resins are exclusively licensed under patent rights of Potomac Affinity Proteins. This product is intended for research purposes only. For commercial applications or manufacturing using these products, commercial licenses can be obtained by contacting the Life Science Group Chromatography Marketing Manager, Bio-Rad Laboratories, Inc., 6000 Alfred Nobel Drive, Hercules, CA 94547, Tel (800)4BIORAD
- Gateway is a registered trademark of Invitrogen Corporation. pDESTand pDEST17 are trademarks of Invitrogen Corporation. QuikChange is a trademark of Stratagene Corporation.



Bio-Rad  
Laboratories, Inc.

Life Science  
Group

Web site [www.bio-rad.com](http://www.bio-rad.com) USA 800 4BIORAD Australia 61 02 9914 2800 Austria 01 877 89 01 Belgium 09 385 55 11 Brazil 55 21 3237 9400  
Canada 905 364 3435 China 86 21 6426 0808 Czech Republic 420 241 430 532 Denmark 44 52 10 00 Finland 09 804 22 00 France 01 47 95 69 65  
Germany 089 318 84 0 Greece 30 210 777 4396 Hong Kong 852 2789 3300 Hungary 36 1 455 8800 India 91 124 4029300 Israel 03 963 6050  
Italy 39 02 216091 Japan 03 6361 7000 Korea 82 2 3473 4460 Mexico 52 555 488 7670 The Netherlands 0318 540666 New Zealand 0508 805 500  
Norway 23 38 41 30 Poland 48 22 331 99 99 Portugal 351 21 472 7700 Russia 7 495 721 14 04 Singapore 65 6415 3188 South Africa 27 861 246 723  
Spain 34 91 590 5200 Sweden 08 555 12700 Switzerland 061 717 95 55 Taiwan 886 2 2578 7189 United Kingdom 020 8328 2000